Skip to Content

Generic Ferriprox Availability

Ferriprox is a brand name of deferiprone, approved by the FDA in the following formulation(s):

FERRIPROX (deferiprone - solution;oral)

  • Manufacturer: APOPHARMA INC
    Approval date: September 9, 2015
    Strength(s): [RLD]

FERRIPROX (deferiprone - tablet;oral)

  • Manufacturer: APOPHARMA INC
    Approval date: October 14, 2011
    Strength(s): [RLD]

Has a generic version of Ferriprox been approved?

No. There is currently no therapeutically equivalent version of Ferriprox available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ferriprox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Use for deferiprone
    Patent 7,049,328
    Issued: May 23, 2006
    Inventor(s): Spino; Michael & Piga; Antonio
    Assignee(s): Apotex Inc.
    A method of treating iron induced cardiac disease in a patient with iron overload, such as in thalassemia or the like comprising administering to the patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
    Patent expiration dates:
    • June 28, 2021
  • Liquid formulation for deferiprone with palatable taste
    Patent 8,703,156
    Issued: April 22, 2014
    Assignee(s): Apotex Technologies Inc.
    An oral pharmaceutical liquid formulation comprising deferiprone and a taste masking composition, said taste masking composition comprising an effective amount of a sweetener (such as sucralose) per liter of liquid composition, an effective amount of a thickening and suspension aid, (for example hydroxyethylcellulose), per liter of liquid composition, an effective amount of a humectant (such as glycerin) per liter of liquid composition, and an effective amount of at least one flavoring agent, wherein a final form of said taste-masked pharmaceutical has a substantially non-bitter and palatable taste.
    Patent expiration dates:
    • October 29, 2029
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • October 14, 2016 - NEW CHEMICAL ENTITY
    • October 14, 2018 - ORPHAN DRUG EXCLUSIVITY
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.